Roche silences Herceptin comparison

Share this article:

Biosimilar Herceptin is coming to India, but marketers will not be able to say so. The Wall Street Journal reported Friday that drugmaker Roche won a case that prevents the biosimilar manufacturer from using the brand name Herceptin in its marketing.

The decision also bars Biocon-Mylan from making comparisons between its lookalike breast cancer treatment's manufacturing processes, safety, efficacy and sales, with those of Herceptin.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.